

"NEW BEGINNING NEW SCIENCE"



Annual Scientific Meeting of **MSGH** 

G U T 2022

19<sup>th</sup> to 21<sup>st</sup> August 2022

Kuala Lumpur Convention Centre Kuala Lumpur, Malaysia

www.msgh.org.my

**MSGH BULLETIN 2022 SUPPLEMENT** 

# **CONTENTS**

MSGH Executive Committee 2021-2023 & Organising Committee, GUT 2022	2
Message from the President, MSGH 2021-2023 & Organising Chair GUT 2022	3
22 <sup>nd</sup> MSGH Oration - Professor Dr Govind K Makharia Citation by Professor Dr Ida Normiha Hilmi	4
19 <sup>th</sup> Panir Chelvam Memorial Lecture - Professor Dr Justin Che-Yuen Wu Citation by Professor Dr Lee Yeong Yeh	5
Programme Summary	6
Daily Programme	
• 19 <sup>th</sup> August 2022 (Friday)	7 - 9
• 20th August 2022 (Saturday)	10 - 12
• 21st August 2022 (Sunday)	13 - 14
Moderators / Chairpersons	15
Faculty Biodata	16 - 29
List of Abstracts	
Lectures & Symposia	30 - 39
E-Poster Presentations	40 - 52
Oral Presentations	53 - 65
Poster Presentations	66 - 222
Floor Plan	223
Trade Exhibition	224
Acknowledgements	225 - 226

#### **MSGH EXECUTIVE COMMITTEE 2021-2023**

**President** Professor Dr Lee Yeong Yeh

President-Elect Datuk Dr Raman Muthukaruppan

Immediate Past President Professor Dr Raja Affendi Raja Ali

Honorary Secretary Dr Haniza Omar

Honorary Treasurer Dr Sattian Kollanthavelu

Executive Committee Members Professor Dr Ida Normiha Hilmi

Datuk Dr Jayaram Menon Dato' Dr Mahendra Raj Dr Nik Razima Wan Ibrahim Datuk Dr Ryan Ponnudurai

Coopted Executive Committee Members Dr Abraham Mathew George

Dr Soon Su Yang Dr Tan Soek Siam

Dr Alex Leow Hwong Ruey

#### **ORGANISING COMMITTEE**

Chair, Organising Committee & Chair, Scientific Committee

Co-Chair, Organising Committee Datuk Dr Raman Muthukaruppan

Co-Chair, Scientific Committee Dr Haniza Omar

Committee Members Professor Dr Raja Affendi Raja Ali Dr Sattian Kollanthavelu

Datuk Dr Jayaram Menon Datuk Dr Ryan Ponnudurai Dato' Dr Mahendra Raj

Professor Dr Ida Normiha Hilmi Dr Nik Razima Wan Ibrahim Dr Abraham Matthew George

Dr Soon Su Yang Dr Tan Soek Siam

Dr Alex Leow Hwong Ruey

#### **MESSAGE**



Dear Colleagues, Friends and Biomedical Industry Partners

The Organising Committee of **GUT 2022** with the theme "**New Beginning, New Science**" welcomes you to join us on 19<sup>th</sup> to 21<sup>st</sup> August 2022 at the Kuala Lumpur Convention Centre (**KLCC**) for the Annual Scientific Meeting of the Malaysian Society of Gastroenterology and Hepatology (MSGH). This year marks a New Beginning post-pandemic, and there are many New Sciences in the field, thus the theme for GUT 2022. As we transit into the 'old normal' post-pandemic, we have decided to hold GUT 2022 as a fully physical meeting to enable interaction

and the bonding of fellowship and camaraderie which will not be possible with a virtual event.

The scientific highlights and sessions will all be recorded and will be made available to registered participants for a limited period after the meeting. The scientific content will not only feature the latest sciences highly relevant to clinical practice but also clinical topics tailored for busy clinicians. Essentially, the programme is designed for everyone with an interest in gut health including primary care practitioners, family physicians, scientists, surgeons, general physicians and gastroenterologists. As a regular feature, the meeting also welcome submissions of high-quality research papers and authors will stand a chance to win our prestigious Young Investigator Awards. In addition, we will have our industry partners at their physical booths welcoming you to their latest offerings in innovative products and other latest information.

I hope to meet up with you in-person.

**Professor Dr Lee Yeong Yeh** 

President, MSGH 2021-2023 & Organising Chair GUT 2022

### 22<sup>ND</sup> MSGH ORATION PROFESSOR DR GOVIND K MAKHARIA

#### Citation by Professor Dr Ida Normiha Hilmi



"Celiac Disease: Opportunities and Challenges"

Professor Dr Govind K Makharia is a Professor in the Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India. He received his training from the prestigious Postgraduate Institute of Medical Education and Research, Chandigarh, India. He has trained 96 fellows in gastroenterology and nine PhD students. He has published 305 articles in indexed journals, 42 book chapters and edited a handbook on celiac disease. He has a h-index of 52 and his publications have been cited 11,000 times. He has been listed amongst the top two

percent of research scientists globally (2021).

Professor Dr Makharia holds many important positions including being the Secretary General of the Indian Society of Gastroenterology; Chair of the Clinical Research Committee, World Gastroenterology Organization; Governing Council Member of the World Gastroenterology Organization; Council Member of the Asian Pacific Association of Gastroenterology and Coordinator of the DBT Consortium on Celiac Disease. In addition to this, he is also the co-inventor of a device for fecal incontinence and a liver biopsy needle (Bioscoop).

Professor Dr Makharia has received many awards including the BMJ South-East Asia Research Paper of the Year Award in 2016, ISG Om Prakash Memorial Award, ISG-Zydus Oration, SR Naik Memorial Award and AlIMS Excellence Awards. He has successfully organised a Young Clinician Programme for the last 11 years involving approximately 900 GI trainees and the first Train-the-Trainers programme on behalf of the Indian Society of Gastroenterology. He has initiated and participated in the development of many global, Asian and Indian practice guidelines on various diseases. His main area of research is Celiac Disease.

In terms of his personal life, Professor Dr Makharia is the loving son to Shyam Lal Makharia and Savitri Makharia and has been blessed with a lovely wife, Dr Suman Lal, who is an obstetrician and gynaecologist. They have a beautiful daughter who is also a doctor; Dr Archita Makharia. He recently expanded his family with Dr Archita's recent marriage with Dr Archit Gupta who is a GI surgeon. His interests outside medicine include travel and music.

Although his illustrious academic career is self-evident, a truly distinguishing feature of Professor Dr Makharia is his warmth, generosity and absolute dedication to patient care and teaching. His lectures have always been outstanding, and I have learned greatly from him over the years; as have a multitude of others. I cannot think of anyone more deserving to present this year's 22<sup>nd</sup> MSGH Oration; Celiac Disease: Opportunities and Challenges.

# 19<sup>TH</sup> PANIR CHELVAM MEMORIAL LECTURE PROFESSOR DR JUSTIN CHE-YUEN WU

### Citation by Professor Dr Lee Yeong Yeh



#### "Functional GI Disorders in Asia: The Past and the Future"

Dr Panir Chelvam, was known for being highly successful in his gastroenterology practice but also a caring family man and a kind friend. Professor Dr Justin Wu fits a similar personality. Having known him for several years now, and from a couple of working opportunities with him, I am greatly delighted to read his citation today.

Professor Dr Justin Wu graduated from the Chinese University of Hong Kong (CUHK) with Distinction in Medicine in 1993. He then underwent internal medicine and gastroenterology training under the supervision of Professor Dr Joseph Sung, much regarded as his close mentor

and a friend. With his deep interest in GI motility, he later pursued further training at the Royal Adelaide Hospital under the supervision of Professor Dr John Dent and Professor Dr Richard Holloway in the year 2000.

Professor Dr Justin Wu joined CUHK as an Associate Professor in 2006 and was then promoted to Professor just three years later. During his tenure, he has academic and clinical focus in the field of functional GI disorder (now termed disorders of gut-brain interactions or DGBIs) and gastroesophageal reflux disease with over 300 publications in top medical journals including the New England Journal of Medicine, Lancet and Gastroenterology with H-index above 50. He is a current member of the Working Group of Chicago Classification for esophageal motility disorders.

Professor Dr Justin Wu held several key leadership positions in many local and international professional organizations. He is the current President of the Asian Pacific Association of Gastroenterology (APAGE), Past President of Hong Kong Society of Gastroenterology (HKSGE), President of APDW 2017, and the Scientific Committee Chairman of Asia Neurogastroenterology and Motility Association (ANMA). He has served as the managing director of Journal of Gastroenterology and Hepatology (JGH), and International Associate Editor of American Journal of Gastroenterology (AJG).

As the Associate Dean (Health Systems) of Faculty of Medicine and the Chairman of CUHK Medical Services, he is responsible for development of collaborative network with private health systems, businesses and industry partners in Hong Kong, Greater Bay Area and beyond. He is former Chief Operating Officer of CUHK Medical Centre, the private teaching hospital of CUHK; the founding director of Asia's first "Global Physician-Leadership Stream" (GPS) of MBChB programme; and the founding director of Hong Kong Institute of Integrative Medicine with the mission of fostering cooperation between Western and Chinese medicine in the health system.

Having a pleasant personality, it is not surprising that Professor Dr Justin Wu is an eminent teacher with eight teaching awards of medical education included the Vice-Chancellor Exemplary Teaching Award, Master Teacher, and Teacher of the Year Awards in CUHK Medicine. He has also actively contributed to the development of medical innovations in Hong Kong. He is serving as director and advisor of numerous biomedical technology companies and investment funds.

Last but not least, he is a caring father who will spend any available time out of his busy schedule with his daughter, Jasmine. There is no doubt that his success is not possible without his supportive spouse, Lily Heung. His outstanding academic achievement, exemplary leadership qualities and continuous pursuit of innovations have brought significant contributions to the field of gastroenterology. We are truly honoured to have Professor Dr Justin Wu to deliver the 19<sup>th</sup> Panir Chelvam memorial lecture.

### **PROGRAMME SUMMARY**

Time Date	19 <sup>th</sup> August 2022 (Friday)	20 <sup>th</sup> August 2022 (Saturday)	21 <sup>st</sup> August 2022 (Sunday)
0830 - 0900	SYMPOSIUM 1 The MSGH Consensus		SYMPOSIUM 6
0900 - 0930		SYMPOSIUM 3 Inflammatory Bowel Disease	New Science Series 2: Joint WGO-MSGH Symposium - Green
0930 - 1000	Statements on MAFLD		GI Practices and Planetary Health
1000 - 1030	<b>LECTURE 1</b> 22 <sup>nd</sup> MSGH Oration	<b>LECTURE 2</b> 19 <sup>th</sup> Panir Chelvam Memorial Lecture	LECTURE 3
1030 - 1100	Break		
1100 - 1130	V 1 A 14	SYMPOSIUM 4 Chronic Hepatitis B: New	Tea Satellite Symposium 3
1130 - 1200	Young Investigator Award 1  Best Oral Paper Presentations		SYMPOSIUM 7
1200 - 1230		Treatment Paradigm	Grand Round Series 2: Overlap
1230 - 1300	Lunch Satellite Symposium 1	Lunch Satellite Symposium 2	Functional GI Disorders
1300 - 1330		Lunch Satellite Symposium 2	CLOSING CEREMONY
1330 - 1400	Break / Friday Prayers	Young Investigator Award 2 & Best E-Poster Award Presentations	
1400 - 1430	bleak / Fliday Flayers	Graduation Ceremony	
1430 - 1500	SYMPOSIUM 2  New Science Series 1: Latest Science in Gut Microbiota	<b>SYMPOSIUM 5</b> Grand Round Series 1 (Joint	
1500 - 1530		Session with PRO-EURO DILI Network): Drug Induced Liver	
1530 - 1600	Latest Science in Gut Microbiota	Injury	
1600 - 1630	Break		
1630 - 1700	Tea Satellite Symposium 1	Tea Satellite Symposium 2	
1700 - 1800		iea sateinte symposium 2	
1900 - 1930	OPENING CEREMONY Opening of Exhibition & Launching of MSGH Website	MSGH Annual General Meeting	
1930 - 2200	APPRECIATION DINNER FOR GUT 2022 & APDW 2021 (By Invitation Only)		

#### **DAILY PROGRAMME**

## 19th August 2022 (Friday)

0830 - 1000 SYMPOSIUM 1 | The MSGH Consensus Statements on MAFLD

Chairpersons: Haniza Omar / Chan Wah Kheong

Introduction

Chan Wah Kheong (Malaysia)

Assessment and Referral Pathway for Metabolic Dysfunction Associated Liver Disease (MAFLD)

Tan Soek Siam (Malaysia)

Current and Emerging Therapy in MAFLD

Vincent Wai-Sun Wong (Hong Kong)

Improving Metabolic Outcomes in MAFLD

Chan Siew Pheng (Malaysia)

Role of Primary Care in the Management of MAFLD

Anis Safura Ramli (Malaysia)

MAFLD - A Public Health Perspective

Feisul Mustapha (Malaysia)

A&Q

1000 - 1030 **LECTURE 1** 

22<sup>nd</sup> MSGH Oration

Citation: Ida Normiha Hilmi

Celiac Disease: Opportunities and Challenges

Govind K Makharia (India)

1030 - 1100 Break

1100 - 1230

Young Investigator Award 1

**Best Oral Paper Presentations** 

# DAILY PROGRAMME 19th August 2022 (Friday)

1230 - 1330 Lunch Satellite Symposium 1 (Abbott)

Chairperson: Alex Leow Hwong Ruey

An Extensive Approach to Manage Overlapping FGID Symptoms (Virtual)

Tim Vanuvtsel (Belgium)

Expert Dialogue Session: Addressing Cultural Gaps in Treating FD-GERD (Virtual)

Tim Vanuytsel (Belgium)

O&A

1330 - 1430 Break / Friday Prayers

1430 - 1600 SYMPOSIUM 2 | New Science Series 1: Latest Science in Gut Microbiota

Chairpersons: Mahendra Raj / Raman Muthukaruppan

Gut Microbiota Dysbiosis in COVID-19: Epiphenomenon or a Meaningful Association?

Uday C Ghoshal (India)

Gut Microbiota in Colorectal Cancer

Wei Shu-Chen (Taiwan)

H.pylori and Gastric Cancer

Hidekazu Suzuki (Japan)

Fecal Microbiota Transplantation

David Ong Eng Hui (Singapore)

Q&A

1600 - 1630 Break

# DAILY PROGRAMME 19th August 2022 (Friday)

#### 1630 - 1800 Tea Satellite Symposium 1

Chairperson: Goh Khean Lee

The Evolving Face of Reflux-Like Symptoms & Its Management (Reckitt)

Peter James Kahrilas (United States)

Chairperson: Goh Khean Lee

The Latest ACG Clinical Guideline for Diagnosis and Management of GERD (AstraZeneca)

Lawrence Ho Khek Yu (Singapore)

Chairpersons: Ida Normiha Hilmi / Lee Yeong Yeh

IBD Monitoring Reimagined: Innovation in IBD Care (Ferring)

Alex Leow Hwong Ruey (Malaysia)

#### 1900 - 1930 **OPENING CEREMONY**

Exhibition Hall

- Opening of Exhibition
- Launching of MSGH Website
- IBD Preceptorship & IBD App

#### 1930 - 2200 APPRECIATION DINNER FOR GUT 2022 & APDW 2021 (By Invitation Only)

Mandarin Oriental Hotel

#### **DAILY PROGRAMME**

### 20<sup>th</sup> August 2022 (Saturday)

0830 - 1000 SYMPOSIUM 3 | Inflammatory Bowel Disease

Chairpersons: Ida Normiha Hilmi / Raman Muthukaruppan

COVID19 and IBD - What have we Learned so Far?

Gilaad G Kaplan (Canada)

Isolated Ileocecal Crohn's Disease: Is it Time to Swing the Pendulum Back to Surgery?

**Yes:** Khong Tak Loon (Malaysia) **No:** Govind K Makharia (India)

Case 1: How to Position Small Molecules and Biologics in IBD?

Nazri Mustaffa (Malaysia)

Case 2: Management of Acute Severe Colitis

Nik Razima Wan Ibrahim (Malaysia)

Q&A

1000 - 1030 **LECTURE 2** 

19th Panir Chelvam Memorial Lecture

Citation: Lee Yeong Yeh

Functional GI Disorders in Asia: The Past and the Future

Justin Che-Yuen Wu (Hong Kong)

1030 - 1100 Break

1100 - 1230 SYMPOSIUM 4 | Chronic Hepatitis B: New Treatment Paradigm

Chairpersons: Haniza Omar / Sattian Kollanthavelu

Can we do More with Current HBV Treatment with Nucleoside Analogues?

Vincent Wai-Sun Wong (Hong Kong)

Debatable Among Global Hepatitis B Guidelines: How do we Manage Patients?

Teerha Piratvisuth (Thailand)

An Overview of Emerging Therapies for Functional Cure

Lim Seng Gee (Singapore)

Asian Pacific Association for the Study of Liver (APASL) Guidelines: Hepatitis B Virus in Pregnancy

Manoj Kumar Sharma (India)

Q&A

# DAILY PROGRAMME 20th August 2022 (Saturday)

1230 - 1330 Lunch Satellite Symposium 2 (Takeda)

Chairperson: *Raja Affendi Raja Ali*Are we doing Enough in Treating GERD? *Daphne Ang Shih Wen (Singapore)* 

Paving the Way Towards Disease Modification in Crohn's Disease

Wei Shu-Chen (Taiwan)

Q&A

1330 - 1430 Young Investigator Award 2 & Best E-Poster Award Presentations

**Graduation Ceremony** 

1430 - 1600 SYMPOSIUM 5 | Grand Round Series 1 (Joint Session with PRO-EURO DILI Network):

**Drug Induced Liver Injury** 

Chairpersons: Tan Soek Siam / Jayaram Menon

Introduction to PRO-EURO-DILI Network

Raul J Andrade (Spain)

 $\label{lem:condition} \textbf{Approach and Management of DILI in Real-Life Practice - The Asian Experience}$ 

Harshad Devarbhavi (India)

Approach and Management of DILI in Real-Life Practice - The European Experience

Raul J Andrade (Spain)

Case 1: COVID-19 Vaccine Induced Liver Injury

Hoo Chai Zhen (Malaysia)

Case 2: Immunotherapy-Associated Liver Injury

Raul J Andrade (Spain)

Q&A

1600 - 1630 Break

# DAILY PROGRAMME 20th August 2022 (Saturday)

1630 - 1800 Tea Satellite Symposium 2

Chairperson: Lee Yeong Yeh

The Impact of Antibiotics on the Gut Microbiota and Role of Probiotic (Servier)

Kok-Ann Gwee (Singapore)

Chairperson: Lee Yeong Yeh

Define and Optimize the Role of Lenvatinib in HCC Management (Eisai)

Teerha Piratvisuth (Thailand)

Chairperson: Chan Wah Kheong

Mounting Evidence with Immunotherapy in Unresectable HCC (Roche)

Lim Seng Gee (Singapore)

1800 - 1900 MSGH Annual General Meeting

#### **DAILY PROGRAMME**

### 21st August 2022 (Sunday)

0830 - 1000 SYMPOSIUM 6 | New Science Series 2: Joint WGO-MSGH Symposium - Green GI Practices and Planetary Health

Chairpersons: Jayaram Menon / Abraham Mathew George

The Global Gastroenterology Community to Meet the Challenge of Climate Change

Geoffrey Metz (Australia)

Discussion Forum:

Chairperson: Abraham Mathew George

Moderators: Javaram Menon / Raja Affendi Raja Ali

**Green Endoscopy** 

Andrew Veitch (United Kingdom)

**GI Society Survey** 

Desmond Leddin (Canada)

GI Carbon Footprint

Geoffrey Metz (Australia)

**Moving Forward** 

Bishr Omary

Discussion / Q&A

1000 - 1030 LECTURE 3 (Johnson & Johnson)

Chairperson: Raja Affendi Raja Ali

Stages of Global Evolution of Inflammatory Bowel Disease

Gilaad G Kaplan (Canada)

1030 - 1100 Break

1100 - 1130 Tea Satellite Symposium 3 (Johnson & Johnson)

Chairperson: Abraham Mathew George

Real World Effectiveness and Safety of Ustekinumab in IBD

Ooi Choon Jin (Singapore)

# DAILY PROGRAMME 21st August 2022 (Sunday)

#### 1130 - 1300 SYMPOSIUM 7 | Grand Round Series 2: Overlap Functional GI Disorders

Chairpersons: Soon Su Yang / Lee Yeong Yeh

 $\label{thm:conditional} \mbox{How do I Approach Overlap Functional GI Disorders in Practice?}$ 

Justin Che-Yuen Wu (Hong Kong)

Case 1: FD-GERD

Hidekazu Suzuki (Japan)

Case 2: FD-IBS

Kok-Ann Gwee (Singapore)

Case 3: FD-Pancreatic Dysfunction

Seiji Futagami (Japan)

Case 4: FD-Constipation *Uday C Ghoshal (India)* 

Q&A

#### 1300 - 1330 CLOSING CEREMONY

- Award Presentation
- Lucky Draw

### **MODERATORS / CHAIRPERSONS**

#### **Abraham Matthew George**

KPJ Johor Specialist Hospital Johor

#### **Chan Wah Kheong**

University Malaya Medical Centre Kuala Lumpur

#### **Goh Khean Lee**

Universiti Malaya and CENGILD Medical Centre Kuala Lumpur

#### **Haniza Omar**

Selayang Hospital Selangor

#### Ida Normiha Hilmi

University Malaya Medical Centre Kuala Lumpur

#### **Jayaram Menon**

Pantai Hospital Ayer Keroh Melaka

#### Lee Yeong Yeh

Hospital Universiti Sains Malaysia Kubang Kerian, Kelantan

#### **Alex Leow Hwong Ruey**

Pantai Hospital Kuala Lumpur Kuala Lumpur

#### Mahendra Raj

Pantai Hospital Kuala Lumpur Kuala Lumpur

#### Raja Affendi Raja Ali

Universiti Kebangsaan Malaysia Medical Centre Kuala Lumpur

#### Raman Muthukaruppan

Hospital Queen Elizabeth Kota Kinabalu, Sabah

#### Sattian Kollanthavelu

Tuanku Ja'afar Hospital Seremban Negeri Sembilan

#### Soon Su Yang

KPJ Kuching Specialist Hospital Sarawak

#### Tan Soek Siam

Selayang Hospital Selangor

# FREQUENCY OF SIGNIFICANT FIBROSIS IN VARIOUS CHRONIC LIVER DISEASES: AN EVALUATION WITH TRANSIENT ELASTOGRAPHY (TE)

Shahreedhan Shahrani<sup>1</sup>, Preetica Mayuri Balakrishnan<sup>2</sup>, Koshni Ravi<sup>2</sup>, Sandeep Singh Gill R S<sup>2</sup>, Chee Sher Wye<sup>2</sup>, Saiful Hasyim Zulkeflie<sup>2</sup>, Ng Ying Zhuang<sup>3</sup>, Lee Wai Kin<sup>4</sup>, Mohamed Amin A K<sup>5</sup>, Sooi Choong Yeong<sup>6</sup>, C Vikneshwaran C K<sup>1</sup>, Nik Arsyad N M A<sup>7</sup>, Ruben Skantha<sup>1</sup>, Mohd Fairul Limun<sup>1</sup>, Abdul Malik Mohamed Talha<sup>8</sup>, Chuah Kee Huat<sup>2</sup>, Khoo Stanley<sup>1</sup>, Ruveena Bhavani<sup>1</sup>, Chan Wah Kheong<sup>2</sup>, Sanjiv Mahadeva<sup>2</sup>

<sup>1</sup>Department of Internal Medicine, University Malaya Medical Centre, Kuala Lumpur, Malaysia

<sup>2</sup>Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia

<sup>3</sup>Department of Internal Medicine, Hospital Sultan Bahyah, Kedah, Malaysia

<sup>4</sup>Department of Internal Medicine, Hospital Seberang Jaya, Selangor, Malaysia

<sup>5</sup>Department of Internal Medicine, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia

<sup>6</sup>Department of Internal Medicine, Hospital Tengku Ampuan Afzan, Pahang, Malaysia

<sup>7</sup>Faculty of Medicine, International Islamic University Malaysia, Pahang, Malaysia

<sup>8</sup>KPJ Seremban Specialist Hospital, Negeri Sembilan, Malaysia

**INTRODUCTION:** Liver biopsy has long been the gold standard to evaluate liver fibrosis. TE was developed as a non-invasive method to assess liver fibrosis by measuring liver stiffness using shear wave velocity. Many studies have proven its' effectiveness as a method for evaluating liver fibrosis. <sup>1-2</sup> The use of TE in UMMC began in 2013.

**OBJECTIVE:** To determine the frequency and aetiology of liver fibrosis and cirrhosis in our local population

**METHOD:** This was a retrospective study conducted at UMMC. Inclusion criteria was all patients who had TE performed from 1 January 2013 to 31 December 2021. Their demographics, clinical characteristics and TE findings were charted.

**RESULTS:** A total of 3066 patients were included, in which 51.7% were males and 48.3% were females. The median CAP value was 271 dB/m. The median E value was 6.5kPa. 11.2% and 11.3% of patients had significant fibrosis (10.1-14.9kPa) and cirrhosis(≥15kPa) respectively. Non-alcoholic fatty liver disease (NAFLD) was noted to be the most common aetiology for fibrosis (32.8%), followed by chronic hepatitis B (CHB) at 25.2%, chronic hepatitis C (CHC) at 6.7% and alcoholic liver disease (ALD) with 1.3%. This finding was also found to be similar in the cirrhosis group (NAFLD 32.5%, CHB 17.2%, CHC 11.9% and ALD 1.4%).


**DISCUSSION:** Our study shows that the most common cause for significant fibrosis and cirrhosis is NAFLD. This is in contrast with previous studies, that reported the most common aetiology being CHB.3-4 This is likely due to the availability of effective treatment for hepatitis B and C. This may also be attributed to the initiation of the national Hepatitis B vaccination program for newborns and the improvement in blood transfusion safety.

**CONCLUSION:** NAFLD has the greatest frequency of fibrosis compared with other aetiologies of liver disease - mainly as there is no effective treatment, unlike viral hepatitis.

#### REFERENCE

- 1. Afdhal N. H. (2012). Fibroscan (transient elastography) for the measurement of liver fibrosis. Gastroenterology & hepatology, 8(9), 605-607
- 2. J., Chanteloup, E., Vergniol, J., Castéra, L., Le Bail, B., Adhoute, X., Bertet, J., Couzigou, P., & de Lédinghen, V. (2006). Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut, 55(3), 403-408. https://doi.org/10.1136/gut.2005.069153
- 3. Qua CS, Goh KL. Liver cirrhosis in Malaysia: peculiar epidemiology in a multiracial Asian country. *J Gastroenterol Hepatol.* 2011 Aug; 26(8):1333-7. doi: 10.1111/j.1440-1746.2011.06732.x. PMID: 21443669.
- 4. Chieng, Jin Yu and Pan, Yan and Liew, Chiat Fong and Mazawawi Muhammad, and Syed Anas Tamamulqomar Said Abu Hassan, (2022) Aetiologies of liver cirrhosis among adult patients attending a hepatology clinic at Selangor, Malaysia. International Journal of Public Health Research, 12 (1). pp. 1493-1501. ISSN 2232-0245

#### **FLOOR PLAN**



### **TRADE EXHIBITION**

BOOTH NO	COMPANY
01	First Pharmaceutical Sdn Bhd
02	Olympus (M) Sdn Bhd
03	Grifols Malaysia Sdn Bhd
04	Hovid Berhad
05	Medic Pro Healthcare Sdn Bhd
07 & 08	Roche (M) Sdn Bhd
09 & 10	Ferring Sdn Bhd
11 & 12	Johnson & Johnson Sdn Bhd
13 & 14	Eisai (M) Sdn Bhd
15 & 16	AstraZeneca Sdn Bhd
17	Sun Pharma Company
18	EP Plus Group Sdn Bhd
19	Al Medical Service Inc
20	United Italian Trading (M) Sdn Bhd

BOOTH NO	COMPANY
21, 22, 23 & 24	Takeda (M) Sdn Bhd
25, 26, 27, & 28	Abbott Laboratories Sdn Bhd
29	Abbvie Sdn Bhd
30	Medi-Life (M) Sdn Bhd
31	SYS Healthcare Sdn Bhd
33	WellmedicHealthcare Sdn Bhd
34	Brego Life Sciences Sdn Bhd
35 & 36	Mylan Healthcare Sdn Bhd
37	Kotra Pharma
38	Boston Scientific (M) Sdn Bhd
39 & 40	Servier Malaysia Sdn Bhd
41	RB (Health) Malaysia Sdn Bhd
42	MiRXES Pte Ltd
43	DCH Auriga Sdn Bhd

### **ACKNOWLEDGEMENTS**

The Organising Committee of the GUT 2022 would like to express its appreciation to the following for their support and contributions:

#### **PLATINUM SPONSORS**





Takeda (M) Sdn Bhd

#### **GOLD SPONSORS**







Ferring Sdn Bhd











#### **ACKNOWLEDGEMENTS**

#### SILVER SPONSORS

































Sdn Bhd


Olympus (M) Sdn Bhd







# A different approach to hemostasis.



COOK





# Hemospray endoscopic hemostat

For more information on Hemospray, visit: hemospray.cookmedical.com

Registered under Act 737 Registration Number: GB475001118818



